Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara®) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial

Contraception

Volumn 80, Issue 1, 2009, Pages 25-33

  Plewig, Gerd ^a   Cunliffe, William J ^b   Binder, Natascha ^c   Höschen, Kornelia ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c GRÜNENTHAL GMBH   (Germany)

Author keywords

Antiandrogenic efficacy; Chlormadinone acetate; Ethinyl estradiol; Moderate acne; Oral contraceptive

Indexed keywords

CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; PLACEBO;

ACNE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; BODY WEIGHT; BREAKTHROUGH BLEEDING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSMENORRHEA; ERYTHROCYTE COUNT; FATIGUE; FEMALE; FLU LIKE SYNDROME; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HIRSUTISM; HUMAN; HUMAN TISSUE; IRRITABILITY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MASTALGIA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NERVOUSNESS; ORAL CONTRACEPTION; OVARY CYST; PARTIAL THROMBOPLASTIN TIME; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEBORRHEA; SELF EVALUATION; SIDE EFFECT; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; VAGINA DISCHARGE; VITAL SIGN; VOMITING;

ACNE VULGARIS; ADOLESCENT; ADULT; ALOPECIA; ANDROGEN ANTAGONISTS; CHLORMADINONE ACETATE; DERMATITIS, SEBORRHEIC; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HIRSUTISM; HUMANS; SEX HORMONE-BINDING GLOBULIN; YOUNG ADULT;

EID: 67349136077     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2009.02.016     Document Type: Article

References (32)

1. Schramm G., and Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg (Belara®). Results of a post-marketing surveillance study. Clin Drug Investig 22 (2002) 221-231
2. Carlborg L. Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Results of a multicenter study. Acta Obstet Gynecol Scand Suppl 134 (1986) 29-32
3. Kaiser E. Effect of a new hormonal contraceptive (Neo-Eunomin) in females with androgenization symptoms. Geburtshilfe Frauenheilkd 44 (1984) 651-655
4. Breckwoldtt M., Zahradnik H., Wieacker P., Orfanos C., and Happle R. Hirsutism (1990), Springer-Verlag, Berlin
5. Terouanne B., Paris F., Servant N., Georget V., and Sultan C. Evidence that chlormadinone acetate exhibits antiandrogenic activity in androgen-dependent cell line. Mol Cell Endocrinol 198 (2002) 143-147
6. Curran M.P., and Wagstaff A.J. Ethinylestradiol/chlormadinone acetate. Drugs 64 (2004) 751-760 discussion 61-2
7. Zahradnik H., Goldberg J., and Andreas J. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception 57 (1998) 103-109
8. Schramm G., and Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties. Contraception 67 (2003) 305-312
9. Winkler U., Daume E., Sudik R., et al. A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel. Eur J Contracept Reprod Health Care 4 (1999) 145-154
10. Worret I., Arp W., Zahradnik H., Andreas J., and Binder N. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 203 (2001) 38-44
11. Cook C., Centner R., and Michaels S. An acne grading method using photographic standards. Arch Dermatol 115 (1979) 571-575
12. ICH Topic E 6 (R1) Guideline for good clinical practice - note for guidance on good clinical practice. (1997).
13. Kaiser R., and Pfleiderer A. Zervixkarzinom (Kollumkarzinom, Cacinoma colli uteri, Gebärmutterhalskrebs). Lehrbuch der Gynäkologie (1989), Thieme, Stuttgart 331-348
14. Breslow N.E., and Day N.E. Statistical methods in cancer research. Volume I - the analysis of case-control studies. IARC Sci Publ (1980) 5-338
15. Armitage P., and Barry G. Statistical methods in medical research. 2nd ed (1987), Blackwell Scientific Publications, London
16. Koch C.G., and Edwards S. Clinical efficacy trials with categorical data. In: Peace K.E. (Ed). Biopharmaceutical statistics for drug development (1988), Marcel Dekker, Inc, New York
17. Redmond G., Olson W., Lippman J., Kafrissen M., Jones T., and Jorizzo J. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 89 (1997) 615-622
18. Erkkola R., Hirvonen E., Luikku J., Lumme R., Mannikko H., and Aydinlik S. Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms. Acta Obstet Gynecol Scand 69 (1990) 61-65
19. Gollnick H., Albring M., and Brill K. The efficacy of oral cyproterone acetate in combination with ethinyloestradiol in acne tarda of the facial type. J Dermatolog Treat 9 (1998) 71-79
20. Mango D., Ricci S., Manna P., Miggiano G., and Serra G. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris. Contraception 53 (1996) 163-170
21. Vartiainen M., de Gezelle H., and Broekmeulen C. Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate. Eur J Contracept Reprod Health Care 6 (2001) 46-53
22. Lucky A., Henderson T., Olson W., Robisch D., Lebwohl M., and Swinyer L. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 37 (1997) 746-754
23. Koltun W., Lucky A.W., Thiboutot D., et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 77 (2008) 249-256
24. Maloney J.M., Arbit D.I., Flack M., McLaughlin-Miley C., and Sevilla C. Use of a low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris. Clin J Womens Health 1 (2001) 123-131
25. Katz H., Kempers S., Akin M., Dunlap F., Whiting D., and Norbart T. Effect of a desogestrel-containing oral contraceptive on the skin. Eur J Contracept Reprod Health Care 5 (2000) 248-255
26. Thiboutot D., Archer D., Lemay A., Washenik K., Roberts J., and Harrison D. A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. Fertil Steril 76 (2001) 461-468
27. Sabatini R., Orsini G., Cagiano R., and Loverro G. Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents. Contraception 76 (2007) 342-347
28. Wishart J. An open study of Triphasil and Diane 50 in the treatment of acne. Australas J Dermatol 32 (1991) 51-54
29. van Vloten W.A., van Haselen C.W., van Zuuren E.J., Gerlinger C., and Heithecker R. The effect of 2 combined oral contraceptives containing drospirenone or cyproterone acetate on moderate acne and suborrhea. Cutis 69 (2002) 2-15
30. Callan A. A GP's guide to the management of acne in women. Mod Med Aust 3 (1995) 54-64
31. Burton J., Laschet U., and Shuster S. Reduction of sebum excretion in man by the antiandrogen, cyproterone acetate. Br J Dermatol 89 (1973) 487-490
32. Mercurio M.G. Hirsutism: diagnosis and management. J Gend Specif Med 4 (2001) 29-34 64